These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 35957613)

  • 1. Immunogenicity of small-cell lung cancer associates with STING pathway activation and is enhanced by ATR and TOP1 inhibition.
    Li X; Li Y; Zhao Z; Miao N; Liu G; Deng L; Wei S; Hou J
    Cancer Med; 2023 Feb; 12(4):4864-4881. PubMed ID: 35957613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer.
    Taniguchi H; Chakraborty S; Takahashi N; Banerjee A; Caeser R; Zhan YA; Tischfield SE; Chow A; Nguyen EM; Villalonga ÁQ; Manoj P; Shah NS; Rosario S; Hayatt O; Qu R; de Stanchina E; Chan J; Mukae H; Thomas A; Rudin CM; Sen T
    Sci Adv; 2024 Sep; 10(39):eado4618. PubMed ID: 39331709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
    Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway.
    Marinello J; Arleo A; Russo M; Delcuratolo M; Ciccarelli F; Pommier Y; Capranico G
    Br J Cancer; 2022 Oct; 127(7):1214-1225. PubMed ID: 35794238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bavachinin Induces G2/M Cell Cycle Arrest and Apoptosis via the ATM/ATR Signaling Pathway in Human Small Cell Lung Cancer and Shows an Antitumor Effect in the Xenograft Model.
    Hung SY; Lin SC; Wang S; Chang TJ; Tung YT; Lin CC; Ho CT; Li S
    J Agric Food Chem; 2021 Jun; 69(22):6260-6270. PubMed ID: 34043345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
    Thomas A; Takahashi N; Rajapakse VN; Zhang X; Sun Y; Ceribelli M; Wilson KM; Zhang Y; Beck E; Sciuto L; Nichols S; Elenbaas B; Puc J; Dahmen H; Zimmermann A; Varonin J; Schultz CW; Kim S; Shimellis H; Desai P; Klumpp-Thomas C; Chen L; Travers J; McKnight C; Michael S; Itkin Z; Lee S; Yuno A; Lee MJ; Redon CE; Kindrick JD; Peer CJ; Wei JS; Aladjem MI; Figg WD; Steinberg SM; Trepel JB; Zenke FT; Pommier Y; Khan J; Thomas CJ
    Cancer Cell; 2021 Apr; 39(4):566-579.e7. PubMed ID: 33848478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
    Taniguchi H; Caeser R; Chavan SS; Zhan YA; Chow A; Manoj P; Uddin F; Kitai H; Qu R; Hayatt O; Shah NS; Quintanal Villalonga Á; Allaj V; Nguyen EM; Chan J; Michel AO; Mukae H; de Stanchina E; Rudin CM; Sen T
    Cell Rep; 2022 May; 39(7):110814. PubMed ID: 35584676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
    Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
    Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
    Rolle CE; Kanteti R; Surati M; Nandi S; Dhanasingh I; Yala S; Tretiakova M; Arif Q; Hembrough T; Brand TM; Wheeler DL; Husain AN; Vokes EE; Bharti A; Salgia R
    Mol Cancer Ther; 2014 Mar; 13(3):576-84. PubMed ID: 24327519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromodomain and hedgehog pathway targets in small cell lung cancer.
    Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
    Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
    Della Corte CM; Sen T; Gay CM; Ramkumar K; Diao L; Cardnell RJ; Rodriguez BL; Stewart CA; Papadimitrakopoulou VA; Gibson L; Fradette JJ; Wang Q; Fan Y; Peng DH; Negrao MV; Wistuba II; Fujimoto J; Solis Soto LM; Behrens C; Skoulidis F; Heymach JV; Wang J; Gibbons DL; Byers LA
    J Thorac Oncol; 2020 May; 15(5):777-791. PubMed ID: 32068166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cGAS/STING/IFN-1 Response in Squamous Head and Neck Cancer Cells after Genotoxic Challenges and Abrogation of the ATR-Chk1 and Fanconi Anemia Axis.
    Zahnreich S; El Guerzyfy S; Kaufmann J; Schmidberger H
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the TGF-
    Lin A; Zhu L; Jiang A; Mou W; Zhang J; Luo P
    Dis Markers; 2022; 2022():8766448. PubMed ID: 36590751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets.
    Krushkal J; Silvers T; Reinhold WC; Sonkin D; Vural S; Connelly J; Varma S; Meltzer PS; Kunkel M; Rapisarda A; Evans D; Pommier Y; Teicher BA
    Clin Epigenetics; 2020 Jun; 12(1):93. PubMed ID: 32586373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
    Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
    Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer.
    Kundu K; Cardnell RJ; Zhang B; Shen L; Stewart CA; Ramkumar K; Cargill KR; Wang J; Gay CM; Byers LA
    Transl Lung Cancer Res; 2021 Nov; 10(11):4095-4105. PubMed ID: 35004241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
    Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
    Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
    Wang Y; Wu L; Yao Y; Lu G; Xu L; Zhou J
    Cancer Lett; 2018 Nov; 436():1-9. PubMed ID: 30118839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.